NC6 0.00% 2.1¢ nanollose limited

Not to mention the expectation of commercial supply of...

  1. 373 Posts.
    lightbulb Created with Sketch. 304
    Not to mention the expectation of commercial supply of Jelli-Grow in mid-2023.
    I think it's interesting in the Cash Flow sheet that they've only got 1.85 quarters of funding remaining, and have not said that they're planning on a cash raise but instead "the company is confident it will have access to sufficient capital when needed".

    R&D tax rebate due soon, second pilot spin with some sales by end of Feb/early March.
    Their R&D spend is relatively low compared to other biotechs, which also means their rebate won't be a big payday. It's going to be dependent on the revenue of the next pilot spin sales whether they will need to do a cash raise by the next quarter.
 
watchlist Created with Sketch. Add NC6 (ASX) to my watchlist
(20min delay)
Last
2.1¢
Change
0.000(0.00%)
Mkt cap ! $3.612M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
1 18688 2.0¢
 

Sellers (Offers)

Price($) Vol. No.
2.2¢ 48800 1
View Market Depth
Last trade - 16.12pm 14/06/2024 (20 minute delay) ?
NC6 (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.